Cure & Advancements/September 12, 2025/2 min read

People with Type 1 Diabetes Say They'd Accept Risks for Access to New Treatments

A new study reveals that patients are willing to tolerate potential side effects if novel therapies offer meaningful improvements to their diabetes management. The finding highlights an important shift in how people think about treatment trade-offs.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Patients with Type 1 diabetes express willingness to accept risks associated with novel therapies in exchange for potential benefits
The study suggests people prioritize meaningful improvements to their condition over avoiding all possible side effects
Understanding patient perspectives on risk-benefit decisions can help guide development and testing of new diabetes treatments
This data reflects real-world patient priorities that differ from purely theoretical or precautionary approaches to drug safety

What the Study Found

Researchers at Breakthrough T1D surveyed people with Type 1 diabetes about their attitudes toward novel therapies. The key finding: many patients indicated they would be willing to accept risks and potential side effects if those new treatments offered meaningful benefits for managing their diabetes.

This willingness suggests that people living with Type 1 diabetes weigh treatment decisions differently than a purely risk-averse approach might assume. Rather than seeking a treatment with zero possible downsides, many respondents prioritized the opportunity for improved health outcomes.

Why This Matters for Research and Development

Patient perspectives on risk and benefit are crucial information for researchers and pharmaceutical companies developing new therapies. Understanding what trade-offs people are willing to make helps shape how trials are designed and what endpoints matter most.

As the field pursues new approaches—from immunotherapies to other novel mechanisms—knowing that patients want access to promising treatments can inform realistic conversations about what 'acceptable risk' means in the Type 1 diabetes community.

A Realistic View of Treatment Options

Living with Type 1 diabetes involves daily management, potential complications, and ongoing medical expenses. Many people recognize that doing nothing carries its own risks. Against that backdrop, the willingness to consider new treatments with potential downsides reflects a practical reality: no current therapy is perfect.

This study underscores an important truth: people with Type 1 diabetes are not passive. They are informed participants in their own care who can thoughtfully weigh complex decisions about whether a novel therapy's potential benefits are worth its possible risks.

Evidence label

Origin: Breakthrough T1D (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.